A phase II trial of Gemzar (gemcitabine), Taxol (paclitaxel), and Platinol (cisplatin) (GTP) in treatment of advanced transitional cell carcinoma of the urothelium.

Trial Profile

A phase II trial of Gemzar (gemcitabine), Taxol (paclitaxel), and Platinol (cisplatin) (GTP) in treatment of advanced transitional cell carcinoma of the urothelium.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2017

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
  • Indications Bladder cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Sep 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
    • 22 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 31 May 2009 Planned number of patients changed from 71 to 71.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top